{
  "id": 14155218,
  "title": "Translumina launches SPARX global trial for drug coated coronary balloons",
  "url": "https://urgent.news/2026/10/13/translumina-launches-sparx-global-trial-for-drug-coated-coronary",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-13T08:25:40.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/translumina-launches-sparx-global-trial-for-drug-coated-coronary-balloons-162741.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Translumina Therapeutics Private Limited has initiated the SPARX Global Randomized Controlled Trial (RCT) to evaluate the efficacy of a drug-coated balloon (DCB)-first strategy against contemporary drug-eluting stents (DES) in patients with complex coronary artery disease. The trial aims to generate comparative evidence to address key clinical questions regarding the safety, efficacy, and long-term outcomes of this treatment strategy. With a focus on complex coronary artery disease, the SPARX trial will enroll 1,380 patients across 10 countries and compare the SPARX DCB-first approach with established paclitaxel-coated balloon technologies. The study's primary endpoint is a one-year Device-Oriented Composite Endpoint (DOCE), and the results are expected to shape future clinical practice and international guideline recommendations.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}